Drug Information

Drug (ID: DG01476) and It's Reported Resistant Information

• Name: Cryptotanshinone
• Synonyms: Cryptotanshinone; 35825-57-1; Tanshinone c; Cryptotanshinon; (R)-1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-phenanthro(1,2-b)furan-10,11-dione; UNII-5E9SXT166N; C19H20O3; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione; (R)-1,6,6-trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione; MLS001049002; 5E9SXT166N; MFCD07636810; SMR000387041; 4733-35-1; 1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl[1,2-b]furan-10,11-dione; (-)-Cryptotanshinone; (1R)-1,6,6-trimethyl-2,3a,7,8,9,11a-hexahydro-1H-naphtho[1,2-g]benzofuran-10,11-dione; SR-01000758222; NSC686518; starbld0002638; SPECTRUM1505812; CHEMBL187460; cid_160254; SCHEMBL5940386; BDBM57938; CHEBI:149838; Phenanthro(1,2-b)furan-10,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-; HMS2269A22; BCP02909; Cryptotanshinone, >=90% (HPLC); Cryptotanshinone, >=98% (HPLC); HY-N0174; ZINC2109876; Cryptotanshinone, analytical standard; s2285; AKOS015895392; BCP9000554; CCG-208561; CS-3276; DB15579; MCULE-9919031730; NSC-686518; NCGC00163650-01; NCGC00163650-02; BS-17094; NCI60_031208; BCP0726000307; N1843; W2147; 825C571; A822990; Q-100429; SR-01000758222-3; SR-01000758222-4; BRD-K33336844-001-05-3; Q27261913; Phenanthro[1,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (1R)-; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g]benzofuran-10,11-dione; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g]benzofuran-10,11-quinone; (R)-(-)-1,6,6-Trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione; (R)-1,2,6,7,8,9-Hexahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione; 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl- (R)-phenanthro(1,2-b)furan-10,11-dione; Phenanthro[1,2-b]furan-10,11-dione,1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-
• Target: .; NOUNIPROTAC; [1]
• IsoSMILES: C[C@H]1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C
• InChI: InChI=1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,10H,4-5,8-9H2,1-3H3/t10-/m0/s1
• InChIKey: GVKKJJOMQCNPGB-JTQLQIEISA-N
• PubChem CID: 160254
• DrugBank ID: DB15579

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Juvenile myelomonocytic leukaemia [ICD-11: 2A42]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) [1]

• Molecule Alteration: Missense mutation; p.E76K (c.226G>A)
• Sensitive Disease: Juvenile myelomonocytic leukaemia [ICD-11: 2A42.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Ba/F3 cells; Colon; Homo sapiens (Human); CVCL_0161
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CellTiter 96 aqueous one solution cell proliferation assay
• Mechanism Description: The missense mutation p.E76K (c.226G>A) in gene PTPN11 cause the sensitivity of Cryptotanshinone by unusual activation of pro-survival pathway

References

• Ref 1: Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)J Med Chem. 2013 Sep 26;56(18):7212-21. doi: 10.1021/jm400474r. Epub 2013 Sep 4.